Table I.
PFS and OS in advanced ESCC after first-line chemotherapy.
| Authors (Refs.) | Date | Country | Total sample size | Size of SCC | Chemotherapy drugs | PFS | OS |
|---|---|---|---|---|---|---|---|
| Cao (11) | 2009 | China | 48 | 46 | Nedaplatin, paclitaxel | 6.1 m | 11.5 m |
| Shim (12) | 2010 | Korea | 38 | 38 | Cisplatin, 5-fluorouracil | 4.5 m | 7.4 m |
| Honda (13) | 2010 | Japan | 41 | 41 | Doxirubicin, cisplatin, 5-fluorouracil | 153 d | 306 d |
| Kim (14) | 2010 | Korea | 39 | 39 | Docetaxel, cisplatin | 5 m | 8.3 m |
| Overman (15) | 2010 | USA | 117 | 17 | Docetaxel, cisplatin, 5-fluorouracil | 5.3 m | 8.9 m |
PFS, progression-free survival; OS, overall survival; ESCC, esophageal squamous cell carcinoma; SCC, squamous cell carcinoma; m, months; d, days.